Crossmark Global Holdings, Inc. Regenxbio Inc. Transaction History

Crossmark Global Holdings, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 10, 2022	SELL	$30.19 - $40.28 $282,276 - $376,618	-9,350 Closed	0 $0
Q3 2021 Oct 21, 2021	BUY	$29.09 - $45.68 $271,991 - $427,108	9,350 New	9,350 $392,000
Q3 2021 Oct 13, 2021	SELL	$29.09 - $45.68 $269,664 - $423,453	-9,270 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$32.46 - $40.48 $649 - $809	20 Added 0.22%	9,270 $360,000
Q1 2021 Apr 15, 2021	BUY	$33.61 - $49.95 $12,099 - $17,982	360 Added 4.05%	9,250 $316,000
Q4 2020 Jan 14, 2021	BUY	$26.52 - $49.35 $235,762 - $438,721	8,890 New	8,890 $403,000
Q3 2019 Oct 09, 2019	SELL	$31.84 - $50.88 $155,060 - $247,785	-4,870 Closed	0 $0
Q2 2019 Jul 09, 2019	SELL	$42.0 - $59.29 $15,120 - $21,344	-360 Reduced 6.88%	4,870 $250,000
Q1 2019 May 02, 2019	BUY	$40.82 - $62.45 $4,898 - $7,494	120 Added 2.35%	5,230 $300,000
Q4 2018 Jan 31, 2019	BUY	$39.11 - $75.15 $89,953 - $172,845	2,300 Added 81.85%	5,110 $214,000
Q3 2018 Nov 08, 2018	BUY	$65.0 - $82.15 $182,650 - $230,841	2,810 New	2,810 $212,000

191

45.4M

184K

56.7K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $314M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.